Lung Cancer Home > Navelbine and Breastfeeding
Due to the unknown risks, the manufacturer of Navelbine (vinorelbine) recommends that women not breastfeed during chemotherapy treatment with this drug. If you are receiving this medication and breastfeeding is something that you are considering, it's important to discuss this with your healthcare provider.
Navelbine® (vinorelbine) is a prescription medication approved for the treatment of a type of lung cancer known as non-small cell lung cancer. At this time, it is unknown whether Navelbine passes through breast milk in humans. The manufacturer of the medication recommends that women who are receiving therapy with Navelbine not breastfeed.
No research has been done on using Navelbine while nursing. Therefore, it is unknown if the drug passes through breast milk, or if it would harm a nursing infant. Although this lack of information is certainly frustrating, it is important to note that studies of medicines are rarely done in breastfeeding women, as this would expose an infant, who would otherwise not benefit from the medication, to potential problems.
Navelbine is associated with potentially serious side effects, including low blood cell counts, infections, and anemia. Because of the risk for these side effects in a nursing infant, it is generally recommended that women not breastfeed during Navelbine treatment.
You should discuss breastfeeding and Navelbine use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.